CD40.RBDv vaccine
/ LinKinVax
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
June 12, 2024
Safety and Immunogenicity of a Sub-unit Protein CD40.RBDv Bivalent COVID-19 Vaccine, Adjuvanted or Not, as a Booster in Volunteers.
(clinicaltrials.gov)
- P1/2 | N=240 | Recruiting | Sponsor: ANRS, Emerging Infectious Diseases | Not yet recruiting ➔ Recruiting | Initiation date: Feb 2024 ➔ May 2024
Enrollment open • Trial initiation date • Infectious Disease • Novel Coronavirus Disease
1 to 1
Of
1
Go to page
1